Drug Trial Radar · NCT06579755
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
800
Actual
Start
Jan 20, 2026
Primary completion
Apr 14, 2027
Study completion Apr 14, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Aug 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 79 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create an immune response in adult and elderly persons. Another aim is to learn about the side effects of TDV in adult and elderly persons in endemic countries who have one or more additional medical conditions (called comorbidities) such as diabetes mellitus, hypertension or a chronic kidney condition. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times.
Conditions
- Dengue Fever
Interventions
TDVBiological
TDV SC injection.
PlaceboOther
Placebo SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post Vaccination at Day 1Time frame: Within 7 days post-vaccination at Day 1
- Number of Participants with Solicited Local (Injection Site) Adverse Events (AEs) Within 7 Days Post Vaccination at Day 90Time frame: Within 7 days post-vaccination at Day 90
- Number of Participants with Solicited Systemic AEs Within 14 Days Post Vaccination at Day 1Time frame: Within 14 days post-vaccination at Day 1
- Number of Participants with Solicited Systemic AEs Within 14 Days Post Vaccination at Day 90Time frame: Within 14 days post-vaccination at Day 90
- Percentage of Participants with Solicited Local (Injection Site) AEs by Severity Within 7 Days Post Vaccination at Day 1Time frame: Within 7 days post-vaccination at Day 1
- Percentage of Participants with Solicited Local (Injection Site) AEs by Severity Within 7 Days Post Vaccination at Day 90Time frame: Within 7 days post-vaccination at Day 90
- Percentage of Participants with Solicited Systemic AEs by Severity Within 14 Days Post Vaccination at Day 1Time frame: Within 14 days post-vaccination at Day 1
- Percentage of Participants with Solicited Systemic AEs by Severity Within 14 Days Post Vaccination at Day 90Time frame: Within 14 days post-vaccination at Day 90
- Percentage of Participants with Any Unsolicited AEs Within 28 Days Post Vaccination at Day 1Time frame: Within 28 days post-vaccination at Day 1
- Percentage of Participants with Any Unsolicited AEs Within 28 Days Post Vaccination at Day 90Time frame: Within 28 days post-vaccination at Day 90
- Percentage of Participants with a Serious Adverse Event (SAE)Time frame: From first vaccination on Day 1 through the end of trial (up to Day 270)
- Geometric Mean Titers (GMTs) of Neutralizing Antibodies by Microneutralization Test (MNT) for Each of the 4 Dengue Virus Serotypes at Day 120Time frame: At Day 120
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Fundacion Huesped - PPDS
Buenos Aires, Argentina
Associacao Obras Sociais Irma Dulce Hospital Santo Antonio
Salvador, Estado de Bahia, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
São José do Rio Preto, São Paulo, Brazil
Singapore General Hospital (SGH)
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Ramathibodi Hospital
Ratchathewi, Bangkok, Thailand
Hospital for Tropical Diseases
Ratchathewi, Krung Thep Maha Nakhon-Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.